Transmucosal drug delivery has advanced significantly over recent decades—from simple liquid formulations to sophisticated mucoadhesive buccal films. Today, technologies such as Mucofilm® provide an effective solution for APIs with poor oral bioavailability, sensitive degradation profiles, or a need for rapid onset of action.
This webinar will explore the regulatory, scientific, and practical considerations of buccal drug delivery systems. You’ll gain insight into how bypassing first-pass metabolism via the oral mucosa can improve therapeutic efficacy, reduce the required dose, and enhance patient compliance—particularly in populations such as children or those with swallowing difficulties.
We will guide you through the development journey of a transmucosal film—from initial permeability testing using models such as Franz cells with porcine mucosa, to prototype assessment and full product development. You’ll also learn what to look for in a trusted CDMO partner specialising in this highly targeted delivery platform.
Mucofilm® is a proven, flexible technology that enables fast-track feasibility assessments. This session will highlight how AdhexPharma’s experience supports early decision-making—helping you determine whether transmucosal delivery is the right route for your compound, before significant resources are committed
Most registrants disappear after the session ends. We help you
open the right doors before, during, and after the webinar.
<span>By ticking this box, you consent to receiving communications from Adhex Pharma related to this topic and other products or services within their portfolio</span>
